Ensysce Biosciences Files 8-K for Bylaw Amendments
Ticker: ENSCW · Form: 8-K · Filed: Dec 3, 2024 · CIK: 1716947
| Field | Detail |
|---|---|
| Company | Ensysce Biosciences, INC. (ENSCW) |
| Form Type | 8-K |
| Filed Date | Dec 3, 2024 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, filing, financials
TL;DR
Ensysce Biosciences filed an 8-K on Dec 3rd for bylaw changes and financial statements.
AI Summary
Ensysce Biosciences, Inc. filed an 8-K on December 3, 2024, reporting amendments to its articles of incorporation or bylaws and financial statements. The filing also confirms the company's principal executive offices are located at 7946 Ivanhoe Avenue, Suite 201, La Jolla, California, 92037.
Why It Matters
This filing indicates potential changes in the company's governance structure or operational rules, which could impact its strategic direction and shareholder rights.
Risk Assessment
Risk Level: low — The filing is procedural and does not disclose new material financial or operational risks.
Key Players & Entities
- Ensysce Biosciences, Inc. (company) — Registrant
- December 3, 2024 (date) — Date of Report
- November 27, 2024 (date) — Date of earliest event reported
- 7946 Ivanhoe Avenue, Suite 201, La Jolla, California, 92037 (location) — Principal executive offices
FAQ
What specific amendments were made to Ensysce Biosciences' articles of incorporation or bylaws?
The filing indicates that amendments were made, but the specific details of these amendments are not provided in the summary information of the 8-K.
What is the significance of the 'Financial Statements and Exhibits' being reported?
This indicates that the company is providing updated financial information or exhibits as part of its regulatory reporting requirements.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on November 27, 2024.
What is the primary business of Ensysce Biosciences, Inc. according to the filing?
The filing lists the Standard Industrial Classification as 'PHARMACEUTICAL PREPARATIONS [2834]', indicating their business is in this sector.
What was Ensysce Biosciences, Inc. previously known as?
The company was formerly known as Leisure Acquisition Corp. before a name change on September 13, 2017.
Filing Stats: 992 words · 4 min read · ~3 pages · Grade level 13.2 · Accepted 2024-12-03 16:15:23
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share ENSC The Nasdaq Stock Mar
Filing Documents
- form8-k.htm (8-K) — 46KB
- ex3-1.htm (EX-3.1) — 12KB
- 0001493152-24-048497.txt ( ) — 235KB
- ensc-20241203.xsd (EX-101.SCH) — 3KB
- ensc-20241203_lab.xml (EX-101.LAB) — 33KB
- ensc-20241203_pre.xml (EX-101.PRE) — 24KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: December 3, 2024 Ensysce Biosciences, Inc. By: /s/ Lynn Kirkpatrick Name: Dr. Lynn Kirkpatrick Title: President and Chief Executive Officer 4